News and Media

Shedding Light on Prescient Therapeutics’ (PTX) Personalised Cancer Treatments

Today, we will acquaint you with the product pipeline of ASX-listed clinical-stage biotechnology company Prescient Therapeutics Limited (ASX:PTX). Prescient Therapeutics is gaining ...
Read More
| News

Shedding Light on Prescient Therapeutics’ (PTX) Personalised Cancer Treatments

Today, we will acquaint you with the product pipeline of ASX-listed clinical-stage biotechnology company Prescient Therapeutics Limited (ASX:PTX). Prescient Therapeutics is gaining ...
Read More
| News

ASX small caps leading the fight against cancer

StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host ...
Read More
| News

From the garage to a COVID-19 vaccine lab

When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2 screening program in partnership with ...
Read More
| News

Prescient Therapeutics raises $7 million to fund cancer treatment pipeline

Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline of innovative cancer treatments. The ...
Read More
| News

Receive Email Updates

To stay fully updated on Prescient Therapeutics Corporate Activity and Company Announcements, please subscribe for up to the minute updates

WEBCAST AND MEDIA

PTX Shareholder Briefing - 4 August

PTX CEO Steven Yatomi Clarke discusses Prescient Therapeutics treatments in detail

Follow us and stay connected